Shiju Shen
No ORCID on file
· 1 paper in corpus
article
2026
BACKGROUND: Elagolix and Myfembree are gonadotropin-releasing hormone (GnRH)-pathway therapies used for endometriosis, but their post-marketing safety reporting patterns remain incompletely characterized. Because spontaneous reporting datab…